Recommended
product-img
  • Products
  • Discover MP Targets
  • Discover Research Areas
  • mProX™ Human CD19 Stable Cell Line

    [CAT#: S01YF-1023-PY224]
    Product Category:
    Membrane Protein Stable Cell Lines
    Subcategory:
    CD Cell Lines

    Datasheet MSDS Request COA

    Certificate of Analysis Lookup
    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
    Lot Number

    Made to Order Inquiry

    Inquiry
    Host Cell Type:
    Membrane Protein Engineering:
    Fluorescent Marker:
    Resistance:
    Deliverable:

    Product Information

    Target Family
    CD
    Target Protein Species
    Human
    Host Cell Type
    HEK293;CHO-K1;SEM;697;REH
    Target Classification
    CD Cell Lines
    Target Research Area
    Immunology Research
    Related Diseases
    Immunodeficiency, Common Variable, 3; Common Variable Immunodeficiency
    Gene ID
    Human:930
    UniProt ID
    Human:P15391

    Product Properties

    Biosafety Level
    Level 1
    Activity
    Yes
    Quantity
    10⁶ cells per vial
    Applications
    CD19 has various applications in the field of cancer treatment. One study found that patients with large B-cell lymphoma who received chimeric antigen receptor (CAR) T-cell therapy had negative outcomes if they had been treated with bendamustine before apheresis. Another study highlighted the importance of considering mantle cell lymphoma in adults with leukemia/lymphoma with blastoid morphology. Additionally, researchers have explored the use of ionizable lipid nanoparticles to deliver plasmid DNA and induce CAR expression in T cells, which could improve the production methods and application of CAR T-cell therapy. Another study focused on enhancing the cytotoxicity of CAR-T cells against low-antigen cancers by incorporating intrinsically disordered regions (IDRs) into CARs. Finally, a study investigated the role of Id3 in deflecting PD-1-mediated immune suppression during graft-versus-host disease (GVHD), highlighting its potential as a target for reducing GVHD and improving T cell-based immunotherapy.

    Protocols

    Please visit our protocols page.

    Customer Reviews

    There are currently no Customer reviews or questions for mProX™ Human CD19 Stable Cell Line (S01YF-1023-PY224). Click the button above to contact us or submit your feedback about this product.

    FAQ

    chat Casey Davis (Verified Customer)

    What is the significance of CD19 in B cell development and cancer therapy? Jan 01 2021

    chat Patrick Liam (Creative Biolabs Scientific Support)

    CD19 is a key marker for B cell development and is targeted in various cancer therapies, especially in CAR T-cell therapy for B-cell malignancies. Jan 01 2021

    chat Cameron Smith (Verified Customer)

    How does CD19-targeted therapy work in leukemia? May 06 2023

    chat Patrick Liam (Creative Biolabs Scientific Support)

    CD19-targeted CAR T-cell therapy has shown significant efficacy in treating leukemia, especially in cases resistant to conventional therapies. May 06 2023
    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR CLINICAL PROCEDURES" For licensing inquiries, please contact
    Send Inquiry Send Inquiry
    Inquiry Basket
    compare

    Go to compare